Atombio joins Y Combinator's W21 batch

Accepted into Y Combinator W21

Atombio is proud to announce its acceptance into the Y Combinator W21 batch. Joining one of the world's leading startup accelerators marks a major milestone for the company as it advances next-generation AI platforms for mRNA sequence optimization. Through the W21 program, Atombio gained access to an exceptional network of founders, researchers, and investors committed to accelerating transformative technologies in biotechnology and therapeutics.

This milestone strengthens Atombio' mission to redefine how mRNA therapeutics are designed by enabling simultaneous optimization across multiple sequence properties, including stability, expression, manufacturability, and delivery performance. Support from Y Combinator further accelerates the company's efforts to build scalable AI systems capable of rapidly engineering high-performance mRNA candidates for vaccines, therapeutics, and synthetic biology applications.